| Images | Sources | Experiment + Assay | Phenotypes | Human Diseases | ||
|---|---|---|---|---|---|---|
|
Fig. 1 op
Lee H et al. (2024) |
Xla Wt + rspo2 MO - left
NF31 (in situ hybridization) |
|
visceral heterotaxy
|
||
|
|
Fig. 1 op
Lee H et al. (2024) |
Xla Wt + rspo2 MO - right
NF19 (in situ hybridization) |
|
visceral heterotaxy
|
||
|
Fig. 2. E F
Deniz E et al. (2023) |
Xtr Wt + cfap45 CRISPR
NF18 (in situ hybridization) |
|
|||
|
|
Fig. 2. E F
Deniz E et al. (2023) |
Xtr Wt + cfap45 CRISPR 2
NF18 (in situ hybridization) |
|
|||
|
Fig. S1 i r1_c2, j
Sempou E et al. (2022) |
Xtr Wt + kcnh6 CRISPR (400pg)
NF16 (in situ hybridization) |
|
|||
|
|
Fig. S1 i r2_c2, j
Sempou E et al. (2022) |
Xtr Wt + kcnh6 CRISPR (400pg)
NF19 (in situ hybridization) |
|
|||
|
Fig. 2 K-R
Kreis J et al. (2022) |
Xla Wt + rab7a MO
NF17 (in situ hybridization) |
||||
|
Fig. 3 C
Maerker M et al. (2021) |
Xla Wt + bicc1
NF20 (in situ hybridization) |
|
|||
|
Sup. Fig. 3 G I
Maerker M et al. (2021) |
Xla Wt + bicc1 MO
NF16 (in situ hybridization) |
|
|||
|
|
Sup Fig. 3 G I
Maerker M et al. (2021) |
Xla Wt + bicc1 MO
NF16 (in situ hybridization) |
|